查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947519

生物技術領域人工智慧市場：依技術（藥物發現與開發、基因組學與基因編輯、精準醫療、生物加工與製造、診斷與成像）、部署類型（雲端、本地部署）和應用領域劃分——全球預測至2036年

AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-based, On-premise), End-use - Global Forecast to 2036
出版日期: | 出版商: Meticulous Research | 英文 277 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

全球生物技術領域人工智慧（AI）市場預計將以21.8%的複合年增長率成長，從2026年的64.1億美元成長到2036年的約461億美元。本報告對全球五大主要地區的生物技術領域人工智慧市場進行了詳細分析，重點關注當前市場趨勢、市場規模、最新發展以及至2036年的預測。

基於廣泛的一手和二手研究以及對市場現狀的深入分析，本報告對關鍵行業驅動因素、限制因素、機會和挑戰進行了影響分析。 推動生物技術領域人工智慧市場成長的關鍵因素包括計算生物學與生物科學的加速融合，以及藥物發現和個人化治療方案的突破性創新。此外，基因組資料集的快速成長、複雜疾病環境下對高通量篩選日益增長的需求，以及先進人工智慧演算法的整合，預計也將為生物技術領域人工智慧企業創造巨大的成長機會。

市場區隔

目錄

第一章：引言

第二章：摘要整理

第三章：市場概覽

  • 市場動態
    • 驅動因素
    • 限制因素
    • 機遇
    • 挑戰
  • 生成式人工智慧及其底層模型對生物技術的影響
  • 監理環境與倫理考量
  • 波特五力分析

第四章：全球生物技術領域人工智慧市場（依技術劃分）

  • 藥物發現與開發
    • 標靶識別與驗證
    • 先導化合物生成與最佳化
    • 臨床前開發
    • 臨床試驗設計與最佳化
  • 基因體學與基因編輯
    • 基因體定序與分析
    • CRISPR與基因治療設計
    • 功能基因體學
  • 精準醫療
    • 患者分層與生物標記發現
    • 治療反應預測
    • 個人化治療方案製定
  • 生物加工與生產
    • 製程優化
    • 品質控制與監測
    • 產量預測與提升
  • 診斷與影​​像
    • 醫學影像分析
    • 數位病理學
    • 疾病檢測與篩檢
  • 其他（蛋白質工程、合成生物學、農業生物技術）

第五章：全球生物技術領域人工智慧市場依部署類型劃分

  • 雲端部署
  • 本地部署
  • 混合部署

第六章：全球生物技術領域人工智慧市場依最終用途劃分

  • 製藥公司
    • 大藥廠
    • 中小型製藥公司
  • 生技公司
  • 研究機構與學術中心
  • 醫院和診斷中心
  • 合約研究組織 (CRO)

第七章：全球生物技術領域人工智慧市場依地區劃分

  • 北美
    • 美國美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 瑞士
    • 義大利
    • 西班牙
    • 荷蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 新加坡
    • 韓國
    • 澳大利亞
    • 其他亞太國家
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲國家非洲

第八章 競爭格局

  • 關鍵成長策略
  • 競爭標竿分析
  • 競爭概覽
    • 行業領導者
    • 市場差異化因素
    • 先鋒企業
    • 新興企業
  • 主要企業市場排名/定位分析（2025 年）

第9章 企業簡介(產業概要，財務概要，產品系列，策略性展開，SWOT分析)

  • IBM Watson Health(IBM Corporation)
  • Google DeepMind(Alphabet Inc.)
  • Microsoft Corporation
  • NVIDIA Corporation
  • BenevolentAI
  • Exscientia plc
  • Recursion Pharmaceuticals, Inc.
  • Insilico Medicine
  • Atomwise, Inc.
  • Insitro
  • PathAI
  • Tempus AI, Inc.
  • SOPHiA GENETICS
  • Freenome Holdings, Inc.
  • Aidoc Medical Ltd.

第10章 附錄

簡介目錄
Product Code: MRHC - 1041787

AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036

According to the research report titled, 'AI in Biotechnology Market by Technology (Drug Discovery & Development, Genomics & Gene Editing, Precision Medicine, Bioprocessing & Manufacturing, Diagnostics & Imaging), Deployment (Cloud-Based, On-Premise), End-Use, and Geography - Global Forecast to 2036,' the global AI in biotechnology market is expected to reach approximately USD 46.1 billion by 2036 from USD 6.41 billion in 2026, at a CAGR of 21.8% during the forecast period (2026-2036). The report provides an in-depth analysis of the global AI in biotechnology market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The major factors driving the growth of the AI in biotechnology market include the accelerating convergence of computational biology and biological sciences and the breakthrough innovations in drug discovery and personalized treatment protocols. Additionally, the rapid expansion of genomic datasets, increasing need for high-throughput screening in complex disease environments, and integration of advanced AI algorithms are expected to create significant growth opportunities for players operating in the AI in biotechnology market.

Market Segmentation

The AI in biotechnology market is segmented by technology (drug discovery & development, genomics & gene editing, precision medicine, bioprocessing & manufacturing, diagnostics & imaging), deployment (cloud-based, on-premise), end-use, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Technology

By technology, the drug discovery & development segment holds the largest market share in 2026, primarily attributed to its critical role in supporting small molecule design, target identification, and accelerated clinical candidate optimization. AI-powered drug discovery platforms provide substantial competitive advantages in biological research and clinical translation. However, the genomics & gene editing segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI for genetic sequence analysis and CRISPR-based therapeutic development. The ability to deliver integrated solutions with proven clinical validation makes advanced genomics AI platforms highly attractive for biotechnology companies.

Based on Deployment

By deployment, the cloud-based segment holds the largest market share in 2026, owing to its scalability and ability to handle massive biological datasets with collaborative research workflows. Cloud-based AI platforms provide superior accessibility for distributed research teams and institutions. The on-premise segment is expected to witness significant growth during the forecast period, driven by the need for data security compliance and the requirement for real-time processing in specialized laboratory environments. Organizations with stringent intellectual property and regulatory requirements continue to favor on-premise deployment models for sensitive research applications.

Based on End-Use

By end-use, the pharmaceutical companies segment holds the largest share of the overall market in 2026, due to their substantial investments in computational biology infrastructure and the need for accelerated drug development pipelines. Pharmaceutical organizations represent the primary adopters of AI biotechnology solutions. The biotechnology companies segment is expected to grow at a significant CAGR during the forecast period, driven by the increasing adoption of AI for research acceleration and the development of specialized AI-powered therapeutic platforms. Academic research institutions and contract research organizations represent emerging segments with growing adoption of advanced AI biotechnology tools.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global AI in biotechnology market with the largest market share, primarily attributed to substantial investments in computational biology infrastructure and the concentration of leading pharmaceutical innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by expanding biotech research capabilities and government initiatives promoting AI-driven healthcare innovation in China, India, and Singapore. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing biotechnology research infrastructure and increasing adoption of advanced AI technologies.

Key Players

The key players operating in the global AI in biotechnology market are IBM Corporation, Microsoft Corporation, Google LLC, NVIDIA Corporation, Schrodinger, Atomwise, Recursion Pharmaceuticals, Exscientia, DeepMind (Alphabet), and various other regional and emerging biotechnology AI solution providers, among others.

Key Questions Answered in the Report-

  • What is the current revenue generated by the AI in biotechnology market globally?
  • At what rate is the global AI in biotechnology market demand projected to grow for the next 7-10 years?
  • What are the historical market sizes and growth rates of the global AI in biotechnology market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of technology, deployment, and end-use are expected to create major traction for the service providers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global AI in biotechnology market?
  • Who are the major players in the global AI in biotechnology market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the global AI in biotechnology market? What are the impacts of these strategic developments on the market?

Scope of the Report:

AI in Biotechnology Market Assessment -- by Technology

  • Drug Discovery & Development
  • Genomics & Gene Editing
  • Precision Medicine
  • Bioprocessing & Manufacturing
  • Diagnostics & Imaging

AI in Biotechnology Market Assessment -- by Deployment

  • Cloud-Based
  • On-Premise

AI in Biotechnology Market Assessment -- by End-Use

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic Research Institutions
  • Contract Research Organizations

AI in Biotechnology Market Assessment -- by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Singapore
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Scope
  • 1.3. Research Methodology
  • 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
    • 3.2.4. Challenges
  • 3.3. Impact of Generative AI and Foundation Models on Biotechnology
  • 3.4. Regulatory Landscape & Ethical Considerations
  • 3.5. Porter's Five Forces Analysis

4. Global AI in Biotechnology Market, by Technology

  • 4.1. Introduction
  • 4.2. Drug Discovery & Development
    • 4.2.1. Target Identification & Validation
    • 4.2.2. Lead Generation & Optimization
    • 4.2.3. Preclinical Development
    • 4.2.4. Clinical Trial Design & Optimization
  • 4.3. Genomics & Gene Editing
    • 4.3.1. Genome Sequencing & Analysis
    • 4.3.2. CRISPR & Gene Therapy Design
    • 4.3.3. Functional Genomics
  • 4.4. Precision Medicine
    • 4.4.1. Patient Stratification & Biomarker Discovery
    • 4.4.2. Treatment Response Prediction
    • 4.4.3. Personalized Treatment Planning
  • 4.5. Bioprocessing & Manufacturing
    • 4.5.1. Process Optimization
    • 4.5.2. Quality Control & Monitoring
    • 4.5.3. Yield Prediction & Enhancement
  • 4.6. Diagnostics & Imaging
    • 4.6.1. Medical Imaging Analysis
    • 4.6.2. Digital Pathology
    • 4.6.3. Disease Detection & Screening
  • 4.7. Others (Protein Engineering, Synthetic Biology, Agricultural Biotechnology)

5. Global AI in Biotechnology Market, by Deployment

  • 5.1. Introduction
  • 5.2. Cloud-based
  • 5.3. On-premise
  • 5.4. Hybrid

6. Global AI in Biotechnology Market, by End-use

  • 6.1. Introduction
  • 6.2. Pharmaceutical Companies
    • 6.2.1. Large Pharmaceutical Companies
    • 6.2.2. Small & Medium Pharmaceutical Companies
  • 6.3. Biotechnology Companies
  • 6.4. Research Institutes & Academic Centers
  • 6.5. Hospitals & Diagnostic Centers
  • 6.6. Contract Research Organizations (CROs)

7. Global AI in Biotechnology Market, by Region

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Switzerland
    • 7.3.5. Italy
    • 7.3.6. Spain
    • 7.3.7. Netherlands
    • 7.3.8. Rest of Europe
  • 7.4. Asia-Pacific
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. India
    • 7.4.4. Singapore
    • 7.4.5. South Korea
    • 7.4.6. Australia
    • 7.4.7. Rest of Asia-Pacific
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Argentina
    • 7.5.4. Rest of Latin America
  • 7.6. Middle East & Africa
    • 7.6.1. Saudi Arabia
    • 7.6.2. UAE
    • 7.6.3. Israel
    • 7.6.4. South Africa
    • 7.6.5. Rest of Middle East & Africa

8. Competitive Landscape

  • 8.1. Overview
  • 8.2. Key Growth Strategies
  • 8.3. Competitive Benchmarking
  • 8.4. Competitive Dashboard
    • 8.4.1. Industry Leaders
    • 8.4.2. Market Differentiators
    • 8.4.3. Vanguards
    • 8.4.4. Emerging Companies
  • 8.5. Market Ranking / Positioning Analysis of Key Players, 2025

9. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)

  • 9.1. IBM Watson Health (IBM Corporation)
  • 9.2. Google DeepMind (Alphabet Inc.)
  • 9.3. Microsoft Corporation
  • 9.4. NVIDIA Corporation
  • 9.5. BenevolentAI
  • 9.6. Exscientia plc
  • 9.7. Recursion Pharmaceuticals, Inc.
  • 9.8. Insilico Medicine
  • 9.9. Atomwise, Inc.
  • 9.10. Insitro
  • 9.11. PathAI
  • 9.12. Tempus AI, Inc.
  • 9.13. SOPHiA GENETICS
  • 9.14. Freenome Holdings, Inc.
  • 9.15. Aidoc Medical Ltd.

10. Appendix

  • 10.1. Questionnaire
  • 10.2. Related Reports